Superb Microvascular Imaging for the Evaluation of Neuralgic Amyotrophy: A Proof of Concept Study
IRB Number: 2024-1706
March 17, 2025
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Principal Investigator
Co-Investigators
Summary of Study Intervention:
Superb microvascular imaging (SMI) is a novel ultrasound technology that can detect blood flow around nerves. The purpose of this study is to use SMI to better understand Parsonage Turner Syndrome, with the goal of improving understanding and treatment of this mysterious disease. We will enroll six patients through December 31, 2026. Participation involves a one-time visit that includes a clinical examination, an ultrasound, and a brief survey. Participants will be reimbursed $150 at the time of the visit, and up to an additional $100 for transportation and parking costs.
Inclusion/Exclusion Criteria:
Individuals ages 18+ with Parsonage Turner Syndrome may be eligible for the study. We are studying patients with involvement of the radial nerve, median nerve, and/or the anterior interosseous nerve. Participants must have diagnosis confirmed with clinical exam and electrodiagnostic testing.
Patients who cannot tolerate ultrasound, have had a prior surgical procedure on the aforementioned nerves, or a perineural injection within the last 6 months, or have a history of uncontrolled diabetes mellitus, connective tissue disorder, or another vasculopathy are ineligible for this study.
Contact Information for the Study:
Nicky Wang